Eaton Joins Forces With EU-supported Flow Consortium to Develop and Demonstrate Integrated Electric Vehicle Charging Infrastructure
5.7.2022 12:00:00 EEST | Business Wire | Press release
Intelligent power management company Eaton today announced its involvement in a pan-European research and innovation project to deliver the integrated technologies and business models needed to support mass deployment of electric vehicle charging infrastructure.
Supported by the European Union’s Horizon Europe Research and Innovation program, the €9.87M ($10.41M) project will span four years to March 2026, its scope covering the entire electric vehicle charging value chain. The FLOW project consortium, which includes 24 external partners and six leading universities across Europe, will be led by the Fundació Institut De Recerca En Energia De Catalunya.
Eaton’s role in the consortium will involve further developing electric vehicle charging technologies, as well as demonstrating electric vehicle charging solutions, based on experience advancing its Buildings as a Grid approach to uniting the power needs of buildings and electric vehicles with on-site renewable energy generation.
The research and innovation focus will extend across vehicle-to-grid (V2G) and vehicle-to-everything (V2X) capabilities that enable more system flexibility; DC-DC charging (direct current to direct current) that yields both power quality and control benefits; and further work on Eaton’s proprietary Buildings as a Grid Energy Management System that supports forecasting, optimization, and other essential services. To combine the various technologies into a complete solution, several Eaton business units will collaborate on the project—including the pan-European Eaton Research Labs team and the Eaton Center for Intelligent Power in Dublin, Ireland.
Stefan Costea, regional technology manager, Eaton Research Labs, said: “As electric vehicles grow in popularity across Europe, a comprehensive range of fully integrated charging technologies is urgently needed to support mass deployment and enable valuable new services. As a key partner in the FLOW project, we’re thrilled to be developing optimal solutions for electric vehicle charging, V2G, V2X, and energy management. We will demonstrate these technologies at three test labs—at the Eaton European Innovation Center in Prague, at University College Dublin, and at the Fundació Institut De Recerca En Energia De Catalunya, in Barcelona. Additionally, we will be supporting large scale technology demonstrations in Rome and Copenhagen with our energy management systems.”
For the demonstrations in Prague and Barcelona, Eaton will be collaborating closely with Heliox, a market leader in fast charging solutions. University College Dublin and nearby Maynooth University will work with Eaton in Ireland, while RWTH Aachen University , in Germany, will partner with Eaton in Prague on a techno-economic analysis of electric vehicle charging infrastructure use cases. In Rome and Copenhagen, Eaton will collaborate on energy management system interoperability with companies well-known for transmission and distribution: ENEL, Terna, and Areti, in addition to partners at Ricerca Sul Sistema Energetico and the Technical University of Denmark.
Tim Darkes, President, Corporate and Electrical, EMEA, Eaton, explained the context for Eaton’s involvement in the FLOW consortium, saying: “Our work on integrating charging infrastructure into buildings is supporting the rapid move to electric vehicles as part of the energy transition and we’re very proud to be investing heavily in the people, technologies, and programs to accelerate the global drive towards a low-carbon future.”
Jörgen von Bodenhausen, senior manager, Government Programs, Eaton, also added: “We continually seek out opportunities to combine our global scale and expertise with that of world-class industrial and academic partners, thus magnifying our own innovation efforts. From building-in energy management, to DC-DC charging, our work on the FLOW project will help pioneer new solutions to accelerate the commercialization and mass deployment of electric vehicle charging infrastructure and create whole new value propositions for both companies and customers.”
About Eaton
Eaton is an intelligent power management company dedicated to improving the quality of life and protecting the environment for people everywhere. We are guided by our commitment to do business right, to operate sustainably and to help our customers manage power ─ today and well into the future. By capitalizing on the global growth trends of electrification and digitalization, we’re accelerating the planet’s transition to renewable energy, helping to solve the world’s most urgent power management challenges, and doing what’s best for our stakeholders and all of society.
Founded in 1911, Eaton has been listed on the NYSE for nearly a century. We reported revenues of $19.6 billion in 2021 and serve customers in more than 170 countries. For more information, visit www.eaton.com. Follow us on Twitter and LinkedIn.
###
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220705005048/en/
Contact information
Nathalie Lapoirie
NathalieLapoirie@eaton.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 09:00:00 EET | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greatest difference between treatment groups was observed at Week 6 (adjusted mean difference, −1.14 points; p=0.0488).
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
